Transforming Systemic Mastocytosis Care with TKIs: A New Era in Treatment

Unlock the Future of Systemic Mastocytosis Care

Breakthroughs in Targeted Therapy Are Redefining the Standard of Care

Now on demand

For years, systemic mastocytosis posed a persistent challenge — no cure, limited options, and treatments centered on managing symptoms rather than addressing the root cause. That paradigm is now shifting.

Advances in tyrosine kinase inhibitor (TKI) therapy are transforming disease management, allowing for greater symptom control and measurable improvements in patients’ quality of life. With several next‑generation TKIs currently in late‑stage clinical trials, the outlook for patients and providers alike is more promising than ever.

In this expert‑led webinar, you will learn to:

• Identify the newest developments in TKI therapies and their clinical implications.
• Evaluate when to initiate targeted treatment based on disease stage and patient characteristics.
• Apply evidence‑based strategies to optimize safety, monitor response, and manage adverse events.
• Incorporate emerging data into practice to improve patient outcomes and align with evolving standards of care.

Join us to gain the practical insights and clinical confidence you need to deliver the next generation of systemic mastocytosis care.

Reserve your seat today — and be part of the transformation in how this complex disease is treated.

Now on demand

Who should attend:

• Clinicians and care‑team members involved in the management of systemic mastocytosis who want practical insight into emerging targeted therapies and evolving standards of care.
• Nurses, APPs, pharmacists, and allied health professionals seeking evidence‑based guidance on treatment initiation, monitoring, and adverse‑event management in real‑world practice